Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Electromed, Inc.

Ticker
ELMD
Sector
Industry
Report date
November 11, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings call transcripts and news reports highlighting Electromed's financial performance and operational updates through Q1 2027.

Recent developments:
  • Electromed held its Q1 2027 earnings call, providing updates on financial results and business operations [N1].
  • The company conducted its Q4 2026 earnings call, discussing quarterly performance and strategic initiatives [N2].
  • Electromed reported surpassing Q4 earnings estimates, indicating positive financial results for the period [N3].
  • After-hours earnings reports on August 25, 2026, included Electromed among companies reporting financial results [N4].
Overview

Electromed, Inc. is a medical device company focused on airway clearance therapy through its flagship SmartVest® Airway Clearance System. The system delivers High Frequency Chest Wall Oscillation (HFCWO) therapy to patients with compromised pulmonary function, aiming to improve mucus clearance, reduce infections, and enhance quality of life. The company markets primarily to patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions, using a direct-to-patient and provider sales model that includes patient training and insurance claim management. The SmartVest Clearway®, launched in 2022, offers improved patient comfort and usability features. Electromed's market opportunity is supported by clinical evidence and growing awareness of bronchiectasis and related conditions. The company maintains a domestic sales force and support network to drive adoption and market penetration [S1].

Executive summary

Electromed, Inc. develops and markets the SmartVest® Airway Clearance System, a High Frequency Chest Wall Oscillation (HFCWO) therapy device designed to improve respiratory function for patients with compromised pulmonary conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. The company employs a direct-to-patient and provider sales model, bypassing traditional distribution channels, and supports patients with training and insurance claim management. The SmartVest Clearway®, introduced in 2022, features enhanced patient comfort and usability. Clinical evidence supports the therapy's effectiveness in improving quality of life and reducing healthcare utilization. The U.S. market opportunity is underpenetrated, particularly in bronchiectasis patients. Financial data as of September 30, 2026, shows solid liquidity and profitability. Recent earnings calls and news coverage provide ongoing transparency into company performance [S1][S2][N1][N2][N3][N4]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ELMD

Bull case model:

Electromed benefits from a growing market for airway clearance therapy driven by an aging population, increased incidence and awareness of bronchiectasis and related pulmonary conditions, and a shift toward homecare settings. The company’s direct sales model and strong clinical evidence base support adoption and reimbursement. The introduction of the SmartVest Clearway® with enhanced features may improve patient adherence and satisfaction. Internal estimates suggest significant underpenetration in the bronchiectasis patient population, indicating potential for market expansion. Continued investment in clinical studies and patient support services may further validate and differentiate the therapy [S1][N1][N2].

Bear case model:

Risks include potential underdiagnosis and underprescription of HFCWO therapy limiting market penetration. The company’s reliance on physician prescriptions and third-party payers introduces reimbursement and regulatory risks. Competition from alternative airway clearance therapies or new technologies could impact market share. Operational risks include maintaining effective direct sales and support infrastructure and managing insurance claim processes. Clinical outcomes and patient adherence may vary, affecting therapy utilization. Economic or healthcare policy changes could influence reimbursement and patient access [S1].

Moat:

Electromed's moat is built on its proprietary SmartVest® technology, including patented features such as the single-hose design and Soft Start® technology, which enhance patient comfort and therapy effectiveness. The company’s direct-to-patient and provider sales model disintermediates traditional distribution channels, allowing capture of manufacturer and distributor margins and closer patient engagement. Extensive clinical evidence supports the therapeutic benefits of its HFCWO system, reinforcing physician and patient adoption. Regulatory clearance by the FDA and established reimbursement pathways further strengthen market access. The company's focus on patient comfort, ease of use, and comprehensive support services contributes to customer loyalty and adherence, creating barriers to entry for competitors [S1].

Risks overview
Risks summary
The largest risk is the underdiagnosis of bronchiectasis and underprescription of HFCWO therapy, which constrains the addressable market despite clinical benefits.
Risks details:

• Underdiagnosis and Underprescription: Bronchiectasis and related conditions are underdiagnosed, and HFCWO therapy is underprescribed, which may limit market penetration and growth potential.
• Reimbursement and Regulatory Risks: The SmartVest System requires physician prescription and reimbursement approval, exposing the company to risks related to payer policies and regulatory changes.
• Competition: Alternative airway clearance therapies or emerging technologies could reduce demand for Electromed’s products.
• Operational Risks: Maintaining a direct-to-patient sales and support model requires effective management of patient training, insurance claims, and clinician relationships.
• Clinical and Patient Adherence Risks: Variability in clinical outcomes and patient adherence to therapy could impact utilization and perceived effectiveness.

FINAL FORECAST FOR ELMD

Final take one line
Electromed, Inc. demonstrates very high visibility through comprehensive SEC disclosures and recent earnings updates, detailing a specialized airway clearance therapy business with strong clinical support and a growing market opportunity.
Final take 12 to 24 month view

Business trends: Increasing clinical awareness and diagnosis of bronchiectasis and related pulmonary conditions support demand for HFCWO therapy; growth in homecare settings expands market opportunity.
Execution milestones: Continued clinical evidence generation, adoption of the SmartVest Clearway® system, and expansion of direct-to-patient sales and support infrastructure.
Key risks: Underdiagnosis and underprescription of therapy limit market penetration; reimbursement and regulatory challenges; competition from alternative therapies; operational complexities in direct sales and patient support.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy products, primarily the SmartVest® Airway Clearance System, which provides High Frequency Chest Wall Oscillation (HFCWO) therapy to patients with compromised pulmonary function [S1].
  • The SmartVest System includes a programmable air pulse generator, therapy garment, and connecting hose to deliver oscillatory pressure to clear lung secretions, improving respiratory function and reducing infections [S1].
  • Electromed employs a direct-to-patient and provider sales model, obtaining patient referrals from clinicians, managing insurance claims, and delivering and training patients on the SmartVest System for home use, bypassing traditional home medical equipment channels [S1].
  • The company also sells products for acute care settings such as post-surgical or intensive care patients with compromised airway clearance [S1].
  • The SmartVest System is FDA-cleared and available by physician prescription, with two models currently marketed: SmartVest SQL® and SmartVest Clearway®, the latter introduced in November 2022 with enhanced patient experience and modern design features [S1].
  • The SmartVest Clearway System features 360° oscillation coverage, patented Soft Start® technology, an open system design allowing deep breaths during therapy, an intuitive touchscreen interface, and a patented single-hose design for comfort [S1].
  • The company offers a range of garment sizes for pediatric and adult patients, designed for comfort and ease of use to promote adherence to therapy [S1].
  • Electromed’s market focus includes patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and ALS, with sales points including pulmonology clinics, cystic fibrosis centers, neuromuscular clinics, and hospitals [S1].
  • The U.S. homecare market for HFCWO is estimated to grow at approximately 8% annually, with bronchiectasis representing the fastest growing diagnostic category at about 12% annual growth [S1].
  • Bronchiectasis is underdiagnosed but is gaining clinical awareness, including its overlap with COPD, which increases exacerbations and hospitalizations [S1].
  • Clinical studies and retrospective analyses demonstrate that HFCWO therapy with SmartVest improves quality of life, reduces exacerbations, hospitalizations, emergency visits, and antibiotic use in bronchiectasis and COPD patients [S1].
  • Internal company estimates indicate approximately 16% penetration of HFCWO therapy among about one million diagnosed bronchiectasis patients in the U.S., suggesting a large underpenetrated market opportunity [S1].
  • Electromed has a domestic sales force and support network focused on physician, clinician, patient, and payer engagement to drive adoption and market awareness [S1].
  • Financial snapshot as of September 30, 2026 (Q1 FY2027): cash and equivalents of $15.9 million, current assets of $52.2 million, current liabilities of $7.3 million, resulting in a current ratio of 7.19 and cash ratio of 2.19, net income of $2.76 million, basic EPS of $0.33, and diluted EPS of $0.32 [S2].
  • Recent earnings call transcripts and news articles report on quarterly earnings, revenue advances, and operational updates through Q1 2027 [N1][N2][N3][N4].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
  • N1
  • N2
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-08-25 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-11 | www.nasdaq.com | Electromed (ELMD) Q1 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/electromed-elmd-q1-2027-earnings-call-transcript
  • N2 | 2026-09-01 | www.nasdaq.com | Electromed (ELMD) Q4 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/electromed-elmd-q4-2026-earnings-call-transcript
  • N3 | 2026-08-25 | www.nasdaq.com | Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates | https://www.nasdaq.com/articles/electromed-inc-elmd-surpasses-q4-earnings-estimates
  • N4 | 2026-08-25 | www.nasdaq.com | After-Hours Earnings Report for August 25, 2026 : INTU, ZM, HEI, SMTC, BOX, JOYY, NCNO, QFIN, ELMD, STRT | https://www.nasdaq.com/articles/after-hours-earnings-report-august-25-2026-intu-zm-hei-smtc-box-joyy-ncno-qfin-elmd-strt
  • N5 | 2026-08-14 | www.nasdaq.com | InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/inspiremd-inc-nspr-reports-q2-loss-beats-revenue-estimates
  • N6 | 2026-08-13 | www.nasdaq.com | Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/lucid-diagnostics-inc-lucd-reports-q2-loss-lags-revenue-estimates
  • N7 | 2026-08-11 | www.nasdaq.com | DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/dariohealth-corp-drio-reports-q2-loss-lags-revenue-estimates
  • N8 | 2026-08-10 | www.nasdaq.com | Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/envoy-medical-inc-coch-reports-q2-loss-misses-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine